GMTX Gemini Therapeutics, Inc.

Gemini Therapeutics, Inc., a precision medicine company, focuses on the development of new therapies for patients suffering from dry AMD and linked diseases. The company was founded in 2015 and is based in Cambridge, Massachusetts.

As of 11/26/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  08/12/2020
Outstanding shares:  43,112,742
Average volume:  112,518
Market cap:   $133,649,500
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    36870G105
ISIN:        US36870G1058
Sedol:      BKPSYH3
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.89
PS ratio:   0.00
Return on equity:   -38.95%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy